Drug Trial Radar · NCT04433234
Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Jun 30, 2020
Primary completion
Jan 31, 2027
Study completion Jan 31, 2031
Sponsor
- Lead sponsor
- Daiichi Sankyo Co., Ltd.Daiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Jun 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, long-term, extension, phase 2 study to evaluate the safety and efficacy of long-term treatment with DS-5141b in patients with DMD who have completed DS5141-A-J101.
Conditions
- Duchenne Muscular Dystrophy
Interventions
DS-5141bDrug
Administered via subcutaneous injection once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Adverse Events (AEs)Time frame: From first injection to after the last injection of DS-5141b in this study (within approximately 2 years)
- Change in distance walked during 6-minute walk test (6MWT)Time frame: Every 3 months (within approximately 2 years)
- Change in time to stand (TTSTAND)Time frame: Every 3 months (within approximately 2 years)
- Change in time in Timed up and go testTime frame: Every 3 months (within approximately 2 years)
- Change in time in 10-meter Run/Walk testTime frame: Every 3 months (within approximately 2 years)
- Change in score in the North Star Ambulatory Assessment (NSAA)Time frame: Every 3 months (within approximately 2 years)
- Change in score in the Performance of Upper Limb (PUL)Time frame: Every 3 months (within approximately 2 years)
- Change in Left Ventricular Ejection Fraction percentage (LVEF %)Time frame: Every 6 months (within approximately 2 years)
- Change in in Forced Vital Capacity (FVC) (percent predicted)Time frame: Every 6 months (within approximately 2 years)
- Change in Muscle Strength Measured by Quantitative Muscle Strength AssessmentTime frame: Every 3 months (within approximately 2 years)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Kobe University Hospital
Hyōgo, Japan
National Center of Neurology and Psychiatry
Tokyo, Kodaira-Shi, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.